A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for The Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-stimulating Agents
The clinical trial aimed to evaluate the safety and efficacy of once-daily oral vadadustat for treating pediatric participants with anemia of chronic kidney disease who are naive to erythropoiesis-stimulating agents. The study was sponsored by Akebia Therapeutics and was intended to enroll participants aged 4 months to 16 years.
Indication: Anemia of Chronic Kidney Disease
Modality: small molecule
Target: Anemia of Chronic Kidney Disease in Pediatric Patients
Sponsor: Akebia Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Oct 01, 2025
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Anemia of Chronic Kidney Disease in Pediatric Patients
View original source fields
Condition raw: Anemia of Chronic Kidney Disease
Condition normalized: Anemia of Chronic Kidney Disease
Modality raw: Anemia of Chronic Kidney Disease
Modality normalized: small molecule
Target raw: Anemia of Chronic Kidney Disease in Pediatric Patients
Target normalized: Anemia of Chronic Kidney Disease in Pediatric Patients